Drugs / CYC140
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03884829 | Mar 2019 → Nov 2021 | B-cell chronic lymphocytic leukemia, acute myeloid leukemia, adult acute lymphoblastic leukemia, chronic myeloid leukemia +1 | Cyclacel Pharmaceuticals, Inc. | Terminated | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05358379 | Apr 2022 → Aug 2025 | adult lymphoma | Cyclacel Pharmaceuticals, Inc. | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CYC140 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03884829 ↗ |
| Action | Inhibit | “a PLK-1 Inhibitor” NCT03884829 ↗ |
| Route | Other | “Patients will receive CYC140 as a 1 hr infusion once a week for 2 weeks followed by 1 week of rest on an outpatient basis.” NCT03884829 ↗ |
| Target | PLK1 | “a PLK-1 Inhibitor” NCT03884829 ↗ |